n-3 and Trans fatty acids are considered to be the important modifiable factors of the metabolic syndrome. The purpose of this study was to test the hypothesis that lower Omega-3 fatty acids and/or higher trans fatty acids of erythrocytes (RBC) are associated with the risk of the metabolic syndrome. Forty-four patients with the metabolic syndrome, defined by three or more risk factors of the modified Adult Treatment Panel III criteria, and eighty-eight age-and sex-matched controls with less than three risk factors were recruited for the study. The mean age was 54·5 (SEM 0·8) years and 45 % of subjects were female. Trans fatty acids of RBC were higher in patients than controls (0·82 (SEM 0·04) v. 0·73 (SEM 0·03) %; P¼ 0·043), while their Omega-3 indexes, the sum of EPA and DHA in RBC, did not significantly differ (11·78 (SEM 0·04) v. 12·39 (SEM 0·02) %). Multivariableadjusted regression analysis showed positive association between trans fatty acid and risk of the metabolic syndrome (OR 7·13; 95 % CI 1·53, 33·27; P¼ 0·013). Fasting serum insulin (7·9 (SEM 0·7) v. 4·9 (SEM 0·3) mU/ml; P, 0·001) and high sensitivity C-reactive protein (18 (SEM 3) v. 11 (SEM 17) mg/ l; P¼0·042) were also higher in patients than controls. There were significant positive relationships between trans fatty acids and waist circumference, and between trans fatty acids and BMI. The results suggested that RBC trans fatty acids might be a predictor of increased risk for the metabolic syndrome, but n-3 fatty acids were not in this population.
The metabolic syndrome classically refers to a multi-component disorder that is characterized by abdominal obesity, hypertension, dyslipidaemia and impaired glucose tolerance (1) . It is associated with a high risk of subsequent development of type 2 diabetes mellitus and CVD (2) . The prevalence of the metabolic syndrome defined by the Adult Treatment Panel III criteria was 23·7 % in the Third National Examination Survey in the United States, but its prevalence was found to differ among ethnic groups (3) . In Korea, the prevalence of the metabolic syndrome was 29·0 % in men and 16·8 % in women aged 30 -80 years when using Asian -Pacific waist criteria (4) . Serum fatty acid composition has been shown to predict the risk of diabetes (5) and CVD (6) and is related to components of the metabolic syndrome (7) . n-3 PUFA such as EPA (20 : 5n-3) and DHA (22 : 6n-3) have beneficial effects on improving lipid profiles (8, 9) , reducing blood pressure (10) , improving insulin resistance (8, 9) and reducing markers of systemic inflammation (11) . On the other hand, intake of trans fatty acids was inversely related with HDL-cholesterol (12, 13) and positively related to LDL-cholesterol (12) . Trans fatty acids also increased lipoprotein(a) (14) , TAG (15) and insulin resistance (16) and were associated with systemic inflammation and endothelial dysfunction (17, 18) . Thus, n-3 and trans fatty acid tissue levels may be a modifiable factor for the metabolic syndrome. The estimated dietary intake of fish is high in Korea (19) , so Korea is a particularly appropriate population to investigate the role of n-3 PUFA on the metabolic syndrome.
The purpose of the present study was to compare fatty acid composition of erythrocytes (RBC), plasma lipid profiles, high sensitivity C-reactive protein (hs-CRP), fasting glucose and insulin levels between Koreans with and without the metabolic syndrome. The Omega-3 index, a new blood test to measure EPA and DHA in RBC, as a good reflection of systemic n-3 PUFA status (20) was also compared.
Subjects and methods

Subjects
Subjects were recruited from patients visiting for regular heath examinations at Pusan National University Hospital between August 2006 and January 2007. Cases consisted of patients diagnosed with the metabolic syndrome, defined by modified Adult Treatment Panel III criteria (1) : presence of three or more of the following components: (1) a waist circumference $ 90 cm in men and $ 80 cm in women; (2) HDL-cholesterol levels , 400 mg/l in men and , 500 mg/l in women; (3) TAG level $ 1500 mg/l; (4) systolic blood pressure $ 130 mmHg or diastolic blood pressure $ 85 mmHg or taking an anti-hypertensive medication; (5) fasting glucose levels $ 1100 mg/l or taking an anti-diabetic medication. We selected age-and sex-matched controls with less than three risk factors of the modified Adult Treatment Panel III criteria. The current study was approved by the Institutional Review Board of Pusan National University Hospital and informed, written consent was obtained from all subjects before participating.
Procedures
Medical history and lists of medications such as oral hypoglycaemic agents, insulin, lipid-lowering, anti-hypertensive or oestrogen agents were obtained. Weekly total fish intakes were additionally obtained from all subjects. Subjects taking a supplement containing n-3 fatty acids were excluded. Height and body weight was measured using a digital scale with the subjects wearing a light gown. BMI was calculated as weight (kg)/height (m 2 ). Using a tape measure, waist circumference was measured up to 0·1 cm unit at the midpoint between the lower costal margin and the iliac crest by welltrained examiners. Total body fat (%) was determined using a bioelectric impedance analyser (Inbody 3·0; Biospace Co., Ltd., Seoul, Korea). Resting blood pressure was measured using an automatic sphygmomanometer (BP203RV-II; Nippon Colin, Japan) after . 10 min at rest in a sitting position at 08.00 hours to 10.00 hours.
Subjects refrained from smoking or ingesting caffeine for 30 min prior to having their blood samples drawn. Fasting blood samples (. 12 h) were collected from the antecubital vein to determine serum concentrations of total cholesterol, TAG, HDL-cholesterol, fasting glucose, insulin, hs-CRP, alanine aminotransferase (ALT) and alkaline phosphatase. All biochemical analyses were carried out within 2 h of blood sampling, using an autoanalyser (model 7600-110; Hitachi Corp., Tokyo, Japan) and commercially available kits. LDLcholesterol was calculated using the Friedewald formula (21) . Homeostasis model assessment insulin resistance (HOMA-IR) was calculated from the fasting concentration of insulin and glucose using the following formula (22) : HOMA-IR ¼ ðfasting insulin ðmU=mlÞ £ fasting glucose ðmg=dlÞÞ=405:
RBC were used for fatty acid analysis (20) . Boron trifluoride methanol-benzene (B1252; Sigma-Aldrich, MO, USA) was added to RBC and samples were methylated for 10 min at 1008C. Fatty acid methyl esters were analysed by GC (Shimadzu 2010AF; Shimadzu Scientific Instrument, Japan) with a 100 mm SP2560 capillary column (Supelco; Bellefonte, PA, USA). Standard (GLC-727; Nu-Check Prep, Elysian, MN, USA) was used for identifying fatty acids and correcting inter-assay variation. In the standard, 18 : 1t peak was the mixture of 18 : 1n-12t, C18 : 1n-9t and 18 : 1n-7t, while 18 : 2n-6t peak contained 18 : 2n-6tt. The Omega-3 index was calculated as the sum of EPA and DHA in RBC. The control sample composed of pooled RBC and CV was 6·2 %.
Statistical analysis
All data were expressed as mean with their standard errors of the mean. Subjects with and without the metabolic syndrome were compared using the independent t test, and correlation between variables was tested by partial correlation analysis after adjusting age and sex. OR were computed for specific fatty acids of interest using multivariable logistic regression analysis after adjusting for age, sex, height, weight, blood pressure, aspirate aminotransferase, ALT, hs-CRP, glucose, insulin, TAG, total cholesterol, HDLcholesterol, LDL-cholesterol and waist circumference. Fatty acid values were categorized into quartiles based on the control data only and then second and third quartiles were combined. Statistical analysis was performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). A P value of,0·05 was considered statistically significant.
Results
General characteristics of subjects
The characteristics of subjects are shown in Table 1 . Weight, BMI and waist circumference were significantly (P,0·001) higher in the patients with the metabolic syndrome than those without it. Waist circumference (95·5 %) was the most common determinant risk factor in cases, and there were 63·6 % of cases with three risk factors and 34·1 % and 2·3 % of cases with four and five risk factors, respectively. On the other hand, 52·4 %, 23·8 %, 23·8 % of controls had one, none, two risk factor(s), respectively.
Metabolic parameters and fish intake
Diastolic and systolic blood pressure, ALT, hs-CRP, fasting blood glucose, serum insulin, HOMA-IR and TAG were significantly (P,0·05) higher in the patients with the metabolic syndrome than those without it (Table 2) . On the other hand, HDL-cholesterol was significantly (P, 0·001) lower in the patients than in controls. There was no significant difference in the weekly fish consumption between the patients and the control subjects (2·80 servings/week v. 3·11 servings/week). However, subjects with higher fish consumption had a greater Omega-3 index (Fig. 1) . Mean values were significantly different: *P,0·001 (independent t test). † For details of subjects and procedures, see Subjects and methods.
Erythrocyte fatty acid composition
Fatty acid composition of RBC is presented in Table 3 . Trans fatty acids of RBC were significantly (P¼0·043) higher in patients than controls, while the Omega-3 index did not differ between groups. Total PUFA was significantly lower, but 14 : 0, 16 : 1n-t, 18 : 1n-9c, 18 : 2n-6t, 18 : 3n-3 and MUFA were significantly (P, 0·05) higher in the patients with than those without the metabolic syndrome. However, multivariable-adjusted regression analysis showed that only total trans fatty acids and 18 : 2n-6tt were positively (P,0·05) associated with risk of the metabolic syndrome after adjusting for age, sex, height, weight, blood pressure, aspirate aminotransferase, ALT, hs-CRP, glucose, insulin, TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol and waist circumference (Table 4) . Subjects in the highest quartile of total trans fatty acids and 18 : 2n-6tt had seven and fourteen times higher risk of the metabolic syndrome, even after adjusting for all confounding variables. Total trans fatty acids (P¼0·01), 16 : 1n-7t (P¼0·045) and 18 : 2n-6tt (P¼0·007), 14 : 0 (SFA; P, 0·001) and MUFA were positively (P¼0·014) related with waist circumference (Table 5) . BMI was positively associated with 14 : 0 (P, 0·001) and MUFA (P¼0·031), but negatively associated with PUFA (P¼0·023) and n-6 PUFA (P¼ 0·006). TAG levels were positively related with 14 : 0 (P,0·001), 18 : 1n-9c (P, 0·001), 16 : 1 n-7t (P¼0·009) and MUFA (P, 0·001). C-reactive protein was positively related with SFA (P¼0·023), but negatively with PUFA (P¼0·004) and n-6 PUFA (P¼ 0·036). In addition, 14 : 0 was positively associated with glucose (P¼0·009), insulin (P, 0·001) and HOMA-IR (P, 0·001). AST, aspirate aminotransferase; ALT, alanine aminotransferase; hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance, calculated from (fasting insulin (mU/ml) £ fasting glucose (mg/dl))/405. Mean values were significantly different: *P,0·05; **P,0·001 (independent t test).
† For details of subjects and procedures, see Subjects and methods. Omega-3 index, DHA þ EPA. Mean values were significantly different: *P,0·05; **P,0·001 (independent t test). † For details of subjects and procedures, see Subjects and methods.
n-3 and trans fatty acids in metabolic syndrome
Discussion
In the present study, we observed that RBC trans fatty acids were higher in patients with than without the metabolic syndrome and associated with risk of the metabolic syndrome after adjusting for age, sex, height, weight, blood pressure, aspirate aminotransferase, ALT, hs-CRP, glucose, insulin, TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol and waist circumference. However, the Omega-3 index might not be associated with the metabolic syndrome in this population. Total MUFA, PUFA, trans fatty acid, 14 : 0, 16 : 1n-7t, 18 : 1n-9c, 18 : 2n-6tt and 18 : 3n-3 differed between patients and controls, but after adjusting for all metabolic parameters only trans fatty acids and 18 : 2n-6tt were significantly different. Correlation analysis showed that RBC fatty acids were significantly related with mostly TAG, waist circumference and BMI, which might be the major factors accounted for the OR analysis.
Trans fatty acids are positively related with lipoprotein(a) (14) , systemic inflammation, endothelial dysfunction and plasma TAG levels (15) and strongly associated with CVD (18, 23) . Thus, it is possible that trans fatty acids play a role in the development of the metabolic syndrome and type 2 diabetes mellitus (17, 18) . In a large prospective study of trans fatty acids  0·091  0·040  0·003  2 0·001  0·082  0·226*  0·151  16 : 1n-7t  0·118  0·013  0·101  0·092  0·228*  0·176*  0·130  18 : 2n-6t  0·087  0·012  0·031  0·008  0·080  0·234*  0·166 hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance, calculated from (fasting insulin (mU/ml) £ fasting glucose (mg/dl))/405. All values were significantly different: *P,0·05; **P,0·001 (partial correlation coefficient adjusted by age and sex).
† For details of subjects and procedures, see Subjects and methods.
women, intake of trans fatty acids was positively associated with type 2 diabetes (24) . Sun et al. (23) reported that the risk for CHD among subjects in the highest quartile of erythrocyte trans fatty acid content was three times higher than that of subjects in the lowest quartile. Troisi et al. (12) reported that intake of trans fatty acids was positively related to LDLcholesterol and inversely related to HDL-cholesterol. Metaanalysis of Mensink et al. (13) showed that trans fatty acids raised the serum total cholesterol:HDL ratio. Koh-Banerjee et al. (25) reported a positive association between intake of trans fatty acids and abdominal adiposity in the prospective cohort. Kavanagh et al. (26) also showed that trans fatty acids were an independent factor for abdominal fat deposition and impaired insulin sensitivity, both of which are linked to the metabolic syndrome.
Recently, the Korean Food and Drug Administration reported that the average intake of trans fat was estimated as 0·7 % total energy or 1·54 g trans fat per d, which was lower than the WHO recommendation of less than 1 % total energy (27) . The average trans fatty acid of the current subjects was 0·73 % in RBC, which was also lower than those of the USA (2·0 %) and Denmark (1·2 %) (27, 28) . Although RBC trans fatty acids were relatively low in all subjects, they were different between patients and controls, possibly suggesting the association between trans fatty acid and the metabolic syndrome.
Interestingly, we found higher 18 : 2n-6tt and lower 18 : 1t in RBC of subjects as compared with those of Westerners. The main contributors for trans 18 : 2n-6tt are vegetable oils (maize oil, soyabean oil, sesame oil), mayonnaise and canned tuna, while dairy products such as cheese, milk, ice cream, sour cream and butter contain 18 : 1t (29, 30) . It is known that consumption of dairy products is relatively low among Koreans. Thus, this discrepancy can be explained by the dietary pattern between Koreans and Westerners.
Studies have suggested that the genetic regulatory effects of PUFA may protect against the adverse signs of the metabolic syndrome by mediating insulin and carbohydrate control of lipogenic and glycolytic genes, inhibiting fat storage and promoting fat oxidation (31, 32) . Tai et al. (33) found significant gene -nutrient interactions between the PPAR-a gene-leucine to valine (PPARa-L162V) polymorphism and PUFA intake on plasma TAG and apo C-III concentrations in a Framingham Heart Study. In addition, the fatty acid composition in patients with insulin resistance and the metabolic syndrome is typically characterized by high levels of SFA and low levels of PUFA (34) . The present study did not find a difference in PUFA between patients and controls, but PUFA was negatively correlated with hs-CRP and BMI.
n-3 PUFA have beneficial effects in reducing plasma TAG (8) , blood pressure (12) and markers of systemic inflammation such as hs-CRP (13) and also in improving the lipoprotein profile by decreasing the fraction of atherogenic small dense LDL-cholesterol and improving insulin resistance (8, 9) . However, studies showed that EPA and DHA were not significantly different in patients with the metabolic syndrome (34, 35) . We also found no significant association between fish consumption and the metabolic syndrome, and between the Omega-3 index and the metabolic syndrome. In the present study, average fish consumption was three servings per week and was greater than that of US residents, who consumed less than one serving/week (36, 37) . Although the Omega-3 index was not significantly (11·8 (SEM 2·5) % v. 12·4 (SEM 1·9) %, P¼0·123) different between patients with and without the metabolic syndrome, it was higher than in US residents and Europeans (4 %). The current subjects consumed more than the American Heart Association recommendation of fish (38) and had a higher Omega-3 index than the recommended value of 8-10 % to prevent CHD (20) . This may be explained by the fact that Pusan is a major port for the Korean fish market; thus, most people may have higher fish consumption than the general population. The average Omega-3 index was 4 % in the USA (39) and Europe (40) ; thus, Korea is a particularly appropriate population to investigate the role of n-3 PUFA.
In conclusion, this study showed that RBC trans fatty acid content was higher in patients with the metabolic syndrome compared with controls and was associated with risk of the metabolic syndrome after adjusting for age, sex and metabolic parameters. Although causal relationships cannot be ascertained in such a case -control study, these findings have suggested that trans fatty acids might contribute to the metabolic syndrome phenotype. Even though there was no relationship with the Omega-3 index, further studies in populations with lower fish intake regarding the relationship between fish intake and the metabolic syndrome should be undertaken.
